TLDR

The FDA approved Corcept’s Lifyorli (relacorilant) for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
CORT stock surged roughly 40% on the news Wednesday
The FDA completed the review 2.5 months ahead of schedule
Clinical trial data showed overall survival of 16 months vs. 11.9 months for the single-agent treatment
Corcept has a market cap of around $3.97 billion and average analyst target price of $66.80

The FDA gave the green light Wednesday to Corcept Therapeutics’ cancer drug relacorilant, sold under the brand name Lifyorli. The drug is approved in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Corcept Therapeutics Incorporated, CORT

The stock jumped around 40% on the news — one of the bigger single-day moves in the biotech space this year.

Approval is limited to patients who have gone through one to three prior systemic treatment regimens, including at least one with bevacizumab. That’s a specific but meaningful patient population in a hard-to-treat cancer type.

The FDA finished its review 2.5 months ahead of its original goal date. That kind of early completion is rare and signals the agency saw a clear benefit in the data.

What the Trial Data Shows

The approval came off the back of the ROSELLA trial — a multicenter study with 381 patients. Half received relacorilant plus nab-paclitaxel, and half received nab-paclitaxel alone.

The combo therapy showed a median progression-free survival of 6.5 months versus 5.5 months for the single drug. Overall survival was 16 months for the combination versus 11.9 months for nab-paclitaxel alone.

Those are modest but real gains in a setting where options are limited. Platinum-resistant ovarian cancer is notoriously difficult to treat, and any improvement in survival data gets attention.

Relacorilant works as a glucocorticoid receptor antagonist. The dosing is 150 mg taken orally once daily over three consecutive days around each nab-paclitaxel infusion.

Nab-paclitaxel is dosed at 80 mg/m² intravenously on days 1, 8, and 15 of a 28-day cycle.

Side Effects and Risks

The prescribing label includes contraindications for patients who need corticosteroids for life-saving purposes. Common side effects reported include decreased hemoglobin and neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.

On the financial side, the company’s picture is mixed. Revenue grew 22.3% over the past three years. Net margin sits at 13.09% and gross margin at a very healthy 98.3%.

Earnings growth, though, dropped 33.3% over the past year. The P/E ratio is at 45.49, which is on the higher end.

The balance sheet looks solid — a current ratio of 2.92 and a debt-to-equity ratio of just 0.01.

Institutional ownership stands at 72.18%. The average analyst price target is $66.80, which suggests there’s still room to the upside even after today’s jump.

Corcept’s Altman Z-Score is 14.14, pointing to financial stability. The Beneish M-Score of -2.81 suggests the company is unlikely to be manipulating its financials.

The 50-day moving average heading into Wednesday was $37.32, and the RSI of 41.26 indicated the stock was not overbought before the surge.

The post Corcept Therapeutics (CORT) Stock Surges 40% After FDA Approves Lifyorli for Ovarian Cancer appeared first on CoinCentral.

---

Filed under: News - @ March 25, 2026 3:26 pm